

R&D for Malaria

References

Introduction

About half of the world's population is at risk of malaria: Kaiser Family Foundation. *The President's Malaria Initiative and Other U.S. Government Global Malaria Efforts*. Washington, DC: Kaiser Family Foundation; 2019. <https://www.kff.org/global-health-policy/fact-sheet/the-u-s-government-and-global-malaria/>.

219 million cases of malaria in 87 countries that claimed the lives of approximately 435,000 people—61% of whom were young children; 2017 marked second consecutive year malaria cases have increased: World Health Organization. *World Malaria Report 2018*. Geneva: World Health Organization; 2018. <https://www.who.int/malaria/publications/world-malaria-report-2018/en/>.

Research successes

Vector-control tools, two tools are responsible for an estimated 78% of malaria cases averted between 2000 and 2015: S Bhatt, Weiss J, et al. The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature International Journal of Science*. 2015; 15(526); 207–211. <https://www.nature.com/articles/nature15535>.

Artemisinin-based combination therapies (ACTs): From plant to medicine: how an ancient plant-based remedy became a modern malaria medicine [blog post]. *Sandoz*. August 25, 2017. <https://www.sandoz.com/stories/access-healthcare/plant-medicine-how-ancient-plant-based-remedy-became-modern-malaria>.

ACTs, 62% decline in malaria mortality between 2000 and 2015: World Health Organization. *World Malaria Report 2016*. Geneva: World Health Organization; 2016. <https://www.who.int/malaria/publications/world-malaria-report-2016/en/>.

The world's first malaria vaccine, RTS,S: PATH. *The RTS,S Malaria Vaccine*. Seattle: PATH; 2019. https://www.malariavaccine.org/sites/www.malariavaccine.org/files/content/page/files/PATH_MVI_RTSS_Fact%20sheet_042019.pdf.

Tafenoquine, a single-dose medicine to prevent the relapse of *Plasmodium vivax* malaria:

Medicines for Malaria Venture website. First single-dose medicine to prevent the relapse of *P. vivax* approved by US FDA page. <https://www.mmv.org/our-impact/achievements/first-single-dose-medicine-prevent-relapse-p-vivax-approved-us-fda>. Accessed September 25, 2019.

US Agency for International Development website. Medicines for Malaria Venture (MMV) page. <https://www.usaid.gov/global-health/health-areas/malaria/research-innovation/medicines-malaria-venture-mmv>. Accessed September 25, 2019.

US FDA approves Krintafel (tafenoquine) for the radical cure of *P. vivax* malaria [press release]. London, UK: GSK; July 20, 2018. <https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria/>.

Tafenoquine, a companion point-of-care diagnostic: Expert Review Panel for Diagnostics approval expands access to a G6PD deficiency test that supports *P. vivax* malaria treatment and elimination initiatives [press release]. Seattle, Washington: PATH; October 3, 2019. Available at <https://www.path.org/articles/expert-review-panel-diagnostics-approval-expands-access-g6pd-deficiency-test-supports-p-vivax-malaria-treatment-and-elimination-initiatives/>.

A child-friendly malaria medicine, Coartem® Dispersible:

Medicines for Malaria Venture website. Key achievements 2018. https://www.mmv.org/sites/default/files/uploads/images/achievements/MMV_KA2018.jpg. Accessed September 25, 2019.

US Agency for International Development website. Medicines for Malaria Venture (MMV) page. <https://www.usaid.gov/global-health/health-areas/malaria/research-innovation/medicines-malaria-venture-mmv>. Accessed September 25, 2019.

Continued progress is possible, not inevitable

Bill & Melinda Gates Foundation and Institute for Health Metrics and Evaluation. *The Goalkeepers Report 2019: How Geography and Gender Stack the Deck For (or Against) You*. Seattle: Bill & Melinda Gates Foundation; 2019. <https://www.gatesfoundation.org/goalkeepers/report/2019-report/#ExaminingInequality>.

Breakthroughs on the brink

Several long-acting injectable malaria prevention drugs, including one supported by NIH which uses nanotechnology: Martin A. Researchers develop long-acting malaria prevention drug. *Homeland Preparedness News*. January 24, 2018. <https://homelandprepnews.com/stories/26379-researchers-develop-long-acting-malaria-prevention-drug/>.

An experimental single-dose cure for *Plasmodium falciparum* malaria, DSM265: Anti-Malarial Shows Promise in Human Clinical Study [press release]. Washington, DC: American Society for Microbiology; March 11, 2019. <https://www.asm.org/Press-Releases/Anti-Malarial-Shows-Promise-in-Human-Clinical-Stud>.

More than a dozen malaria vaccine candidates are in late-stage clinical development: Policy Cures Research. Neglected Disease R&D Product Pipeline. Sydney, Australia: Policy Cures Research; 2019. <https://www.pipeline.policycuresresearch.org/august2017>.

A promising vector control intervention called Attractive Targeted Sugar Bait: Fiorenzano J, Koehler P, Zue R. Attractive toxic sugar bait (ATSB) for control of Mosquitoes and its impact on non-target organisms: a review. *International Journal of Environmental Research and Public Health*. 2017; 14(4): 398. <https://doi.org/10.3390/ijerph14040398>.

A first-of-its kind test that diagnoses malaria using a patient's saliva: Farmer B. Saliva tests to diagnose malaria one step closer as researchers get £1m for trials. *The Telegraph*. October 1, 2019.

<https://www.telegraph.co.uk/global-health/science-and-disease/saliva-tests-diagnose-malaria-one-step-closer-researchers-get/>.

US government investment in malaria R&D

Policy Cures Research. G-FINDER Public Search Tool. Sydney, Australia: Policy Cures Research; 2019.

<https://gfinder.policycuresresearch.org/PublicSearchTool/>. [Early access to 2018 data was provided by Policy Cures Research in December 2019. Data is now available online as of January 30, 2019.]

US government R&D efforts

Kaiser Family Foundation. *The President's Malaria Initiative and Other U.S. Government Global Malaria Efforts*. Washington, DC: Kaiser Family Foundation; 2019. <https://www.kff.org/global-health-policy/fact-sheet/the-u-s-government-and-global-malaria/>.

Kaiser Family Foundation. *The U.S. Department of Defense & Global Health*. Washington, DC: Kaiser Family Foundation; 2012. <https://www.kff.org/global-health-policy/report/the-u-s-department-of-defense-global/>.

US Food & Drug Administration website. Tropical disease priority review voucher program page.

<https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/tropical-disease-priority-review-voucher-program>. Accessed October 23, 2019.